Cited by 665Lipoproteins and Cardiovascular HealthCholesterol and Lipid MetabolismLipid metabolism and disorders

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol

Open access

Stein, Evan A., Mellis, Scott, Yancopoulos, George D., Stahl, Neil, Logan, Douglas, Smith, William B., Lisbon, Eleanor, Gutierrez, Maria, Webb, Cheryle, Wu, Richard, Du, Yunling, Kranz, Therese, Gasparino, Evelyn, Swergold, Gary D.·2012·New England Journal of Medicine

DOI 10.1056/nejmoa1105803

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Proprotein convertase subtilisin/kexin 9 (PCSK9), one of the serine proteases, binds to low-density lipoprotein (LDL) receptors, leading to their accelerated degradation and to increased LDL cholesterol levels. We report three phase 1 studies of a monoclonal antibody to PCSK9 designated as REGN727/SAR236553 (REGN727). METHODS: In healthy volunteers, we performed two randomized, single ascending-dose studies of REGN727 administered either intravenously (40 subjects) or subcutaneously (32 subjects), as compared with placebo. These studies were followed by a randomized, placebo-controlled, multiple-dose trial in adults with heterozygous familial hypercholesterolemia who were receiving atorvastatin (21 subjects) and those with nonfamilial hypercholesterolemia who were receiving treatment with atorvastatin (30 subjects) (baseline LDL cholesterol, >100 mg per deciliter [2.6 mmol per liter]) or a modified diet alone (10 subjects) (baseline LDL cholesterol, >130 mg per deciliter [3.4 mmol per liter]). REGN727 doses of 50, 100, or 150 mg were administered subcutaneously on days 1, 29, and 43. The primary outcome for all studies was the occurrence of adverse events. The principal secondary outcome was the effect of REGN727 on the lipid profile. RESULTS: Among subjects receiving REGN727, there were no discontinuations because of adverse events. REGN727 significantly lowered LDL cholesterol levels in all the studies. In the multiple-dose study, REGN727 doses of 50, 100, and 150 mg reduced measured LDL cholesterol levels in the combined atorvastatin-treated populations to 77.5 mg per deciliter (2.00 mmol per liter), 61.3 mg per deciliter (1.59 mmol per liter), and 53.8 mg per deciliter (1.39 mmol per liter), for a difference in the change from baseline of -39.2, -53.7, and -61.0 percentage points, respectively, as compared with placebo (P<0.001 for all comparisons). CONCLUSIONS: In three phase 1 trials, a monoclonal antibody to PCSK9 significantly reduced LDL cholesterol levels in healthy volunteers and in subjects with familial or nonfamilial hypercholesterolemia. (Funded by Regeneron Pharmaceuticals and Sanofi; ClinicalTrials.gov numbers, NCT01026597, NCT01074372, and NCT01161082.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1105803

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9
Cohen, J., Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K., & Hobbs, H. H. (2005) · Nature Genetics · doi:10.1038/ng1509 · Cited by 1,381
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice
Lagace, T. A., Curtis, D. E., Garuti, R., McNutt, M. C., Park, S. W., Prather, H. B., Anderson, N. N., Ho, Y. K., Hammer, R. E., & Horton, J. D. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29383 · Cited by 681
Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9
Rashid, S., Curtis, D. E., Garuti, R., Anderson, N. N., Bashmakov, Y., Ho, Y. K., Hammer, R. E., Moon, Y.-A., & Horton, J. D. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501652102 · Cited by 679
Molecular Characterization of Loss-of-Function Mutations in PCSK9 and Identification of a Compound Heterozygote
Zhao, Z., Tuakli-Wosornu, Y., Lagace, T. A., Kinch, L. N., Grishin, N. V., Horton, J. D., Cohen, J. C., & Hobbs, H. H. (2006) · The American Journal of Human Genetics · doi:10.1086/507488 · Cited by 642
Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype
Maxwell, K. N., & Breslow, J. L. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402133101 · Cited by 613
A Spectrum of PCSK9 Alleles Contributes to Plasma Levels of Low-Density Lipoprotein Cholesterol
Kotowski, I. K., Pertsemlidis, A., Luke, A., Cooper, R. S., Vega, G. L., Cohen, J. C., & Hobbs, H. H. (2006) · The American Journal of Human Genetics · doi:10.1086/500615 · Cited by 517
Post-transcriptional Regulation of Low Density Lipoprotein Receptor Protein by Proprotein Convertase Subtilisin/Kexin Type 9a in Mouse Liver
Park, S. W., Moon, Y.-A., & Horton, J. D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m410077200 · Cited by 452
A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates
Chan, J. C. Y., Piper, D. E., Cao, Q., Liu, D., King, C., Wang, W., Tang, J., Liu, Q., Higbee, J., Xia, Z., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903849106 · Cited by 371

Flagged first, then by citations

Show all 15 references

Research works printed but not linked: 1

Olsson AG, 2001, Clin Cardiol, 24, III

Sorted by citations

Items 101–200 of 665

Evolution of sequence-defined highly functionalized nucleic acid polymers
Chen, Z., Lichtor, P. A., Berliner, A. P., Chen, J. C., & Liu, D. R. (2018) · Nature Chemistry · doi:10.1038/s41557-018-0008-9 · Cited by 108
Inclisiran for the Treatment of Cardiovascular Disease: the Orion Clinical Development Program
Stoekenbroek, R. M., Kallend, D. G., Wijngaard, P. L. J., & Kastelein, J. J. P. (2018) · Future Cardiology · doi:10.2217/fca-2018-0067 · Cited by 106
PCSK9 Inhibition: From Current Advances to Evolving Future
Liu, C., Chen, J., Chen, H., Zhang, T., He, D., Luo, Q., Chi, J., Hong, Z., Liao, Y., Zhang, S., et al. (2022) · Cells · doi:10.3390/cells11192972 · Cited by 108
Lipoprotein(a), Cardiovascular Disease, and Contemporary Management
Jacobson, T. A. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.09.003 · Cited by 103
A systematic review of PCSK9 inhibitors alirocumab and evolocumab
McDonagh, M., Peterson, K., Holzhammer, B., & Fazio, S. (2016) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2016.22.6.641 · Cited by 103
Living the PCSK9 Adventure: from the Identification of a New Gene in Familial Hypercholesterolemia Towards a Potential New Class of Anticholesterol Drugs
Abifadel, M., Elbitar, S., Khoury, P. E., Ghaleb, Y., Chemaly, M., Moussalli, M.-L., Rabès, J., Varret, M., & Boileau, C. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0439-8 · Cited by 109
Half a Century Tales of Familial Hypercholesterolemia (FH) in Japan
Mabuchi, H. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv16008 · Cited by 102
Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis
Punch, E., Klein, J., Diaba‐Nuhoho, P., Morawietz, H., & Garelnabi, M. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.023328 · Cited by 101
Identification of CAD candidate genes in GWAS loci and their expression in vascular cells
Erbilgin, A., Civelek, M., Romanoski, C. E., Pan, C., Hagopian, R., Berliner, J. A., & Lusis, A. J. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m037085 · Cited by 101
New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs
Norata, G. D., Ballantyne, C. M., & Catapano, A. L. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht088 · Cited by 99
Evolution and Emergence of Therapeutic Monoclonal Antibodies
Foltz, I. N., Karow, M. L., & Wasserman, S. M. (2013) · Circulation · doi:10.1161/circulationaha.113.002033 · Cited by 109
PCSK9: From discovery to therapeutic applications
Farnier, M. (2014) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2013.10.007 · Cited by 99
Antibodies to watch in 2014
Reichert, J. M. (2013) · mAbs · doi:10.4161/mabs.27333 · Cited by 96
Antisense‐mediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): a first‐in‐human randomized, placebo‐controlled trial
van Poelgeest, E. P., Hodges, M. R., Moerland, M., Tessier, Y., Levin, A. A., Persson, R., Lindholm, M., Erichsen, K. D., Ørum, H., Cohen, A. F., et al. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12738 · Cited by 97
Familial hypercholesterolemia: A review
Varghese, M. J. (2014) · Annals of Pediatric Cardiology · doi:10.4103/0974-2069.132478 · Cited by 98
Furin-cleaved Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Is Active and Modulates Low Density Lipoprotein Receptor and Serum Cholesterol Levels
Lipari, M. T., Li, W., Moran, P., Kong-Beltran, M., Sai, T., Lai, J., Lin, S. J., Kolumam, G. A., Zavala‐Solorio, J., Izrael-Tomasevic, A., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.380618 · Cited by 95
Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9
Stein, E. A., & Raal, F. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-022613-090402 · Cited by 89
Self-citation
Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review
White, C. R., Garber, D. W., & Anantharamaiah, G. M. (2014) · Journal of Lipid Research · doi:10.1194/jlr.r051367 · Cited by 91
Porcine Models of Accelerated Coronary Atherosclerosis: Role of Diabetes Mellitus and Hypercholesterolemia
Hamamdzic, D., & Wilensky, R. L. (2013) · Journal of Diabetes Research · doi:10.1155/2013/761415 · Cited by 86
On the function and homeostasis of PCSK9: Reciprocal interaction with LDLR and additional lipid effects
Tavori, H., Rashid, S., & Fazio, S. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.12.017 · Cited by 86
Small molecules as inhibitors of PCSK9: Current status and future challenges
Xu, S., Luo, S., Zhu, Z., & Xu, J. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.11.011 · Cited by 85
Potential of Proprotein Convertase Subtilisin/Kexin Type 9 Based Therapeutics
Stein, E. A., & Swergold, G. D. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0310-3 · Cited by 84
Self-citation
PCSK9 Inhibitors: Mechanisms of Action, Metabolic Effects, and Clinical Outcomes
Hess, C. N., Wang, C. C. L., & Hiatt, W. R. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-042716-091351 · Cited by 87
From genetic associations to genes: methods, applications, and challenges
Qi, T., Song, L., Guo, Y., Chen, C., & Yang, J. (2024) · Trends in Genetics · doi:10.1016/j.tig.2024.04.008 · Cited by 85
The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol
Mayer, G., & Poirier, S. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s36984 · Cited by 89
Loss- and Gain-of-function PCSK9 Variants
Benjannet, S., Hamelin, J., Chrétien, M., & Seidah, N. G. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.399725 · Cited by 87
Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention
Zhu, Y. M., Anderson, T. J., Sikdar, K. C., Fung, M., McQueen, M., Lonn, E., & Verma, S. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306172 · Cited by 83
PCSK9: Regulation and Target for Drug Development for Dyslipidemia
Burke, A. C., Dron, J. S., Hegele, R. A., & Huff, M. W. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104944 · Cited by 74
Causal inference in health and disease: a review of the principles and applications of Mendelian randomization
Lovegrove, C. E., Howles, S., Furniss, D., & Holmes, M. V. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae136 · Cited by 80
PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE
Ason, B. L., van der Hoorn, J. W. A., Chan, J. C. Y., Lee, E. W., Pieterman, E. J., Nguyen, K., Di, M., Shetterly, S., Tang, J. T., Yeh, W., et al. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m053207 · Cited by 83
Efficiency and Safety of Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody on Hypercholesterolemia: A Meta‐Analysis of 20 Randomized Controlled Trials
Li, C., Lin, L., Zhang, W., Zhou, L., Wang, H., Luo, X., Luo, H., Cai, Y., & Zeng, C. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.001937 · Cited by 77
Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Promotes Macrophage Activation via LDL Receptor-Independent Mechanisms
Katsuki, S., Jha, P. K., Lupieri, A., Nakano, T., Passos, L. S. A., Rogers, M. A., BECKER-GREENE, D. R., Le, T.-D., Decano, J. L., Lee, L. H., et al. (2022) · Circulation Research · doi:10.1161/circresaha.121.320056 · Cited by 81
Molecular genetics of coronary artery disease
Ozaki, K., & Tanaka, T. (2015) · Journal of Human Genetics · doi:10.1038/jhg.2015.70 · Cited by 77
Antibody-Based Therapeutics for Atherosclerosis and Cardiovascular Diseases
Ji, E., & Lee, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115770 · Cited by 77
Cytotoxic lymphocytes and atherosclerosis: significance, mechanisms and therapeutic challenges
Kyaw, T. S., Peter, K., Li, Y., Tipping, P. G., Toh, B., & Bobik, A. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13845 · Cited by 73
Low-density lipoprotein cholesterol lowering treatment: the current approach
Crîşmaru, I., Stoian, A. P., Bratu, O. G., Găman, M., Stănescu, A. M. A., Bacalbaşa, N., & Diaconu, C. C. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01275-x · Cited by 73
New Therapeutic Approaches to the Treatment of Dyslipidemia
Rader, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.01.005 · Cited by 75
Loss of Reelin protects against atherosclerosis by reducing leukocyte-endothelial cell adhesion and lesion macrophage accumulation
Ding, Y., Huang, L., Xian, X., Yuhanna, I. S., Wasser, C. R., Frotscher, M., Mineo, C., Shaul, P. W., & Herz, J. (2016) · Science Signaling · doi:10.1126/scisignal.aad5578 · Cited by 72
Pharmacogenomics in diabetes mellitus: insights into drug action and drug discovery
Zhou, K., Pedersen, H., Dawed, A. Y., & Pearson, E. R. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.51 · Cited by 72
ODYSSEY MONO: Effect of Alirocumab 75 Mg Subcutaneously Every 2 Weeks As Monotherapy Versus Ezetimibe Over 24 Weeks
Roth, E. M., & McKenney, J. M. (2015) · Future Cardiology · doi:10.2217/fca.14.82 · Cited by 69
Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol
Bardolia, C., Amin, N. S., & Turgeon, J. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.789931 · Cited by 69
Malfolded Protein Structure and Proteostasis in Lung Diseases
Balch, W. E., Sznajder, J. I., Budinger, S., Finley, D. J., Laposky, A. D., Cuervo, A. M., Benjamin, I. J., Barreiro, E., Morimoto, R. I., Postow, L., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201306-1164ws · Cited by 70
Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia
Burnett, J., Bell, D. A., Hooper, & Watts, G. F. (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s28581 · Cited by 69
Integrating evolutionary and regulatory information with a multispecies approach implicates genes and pathways in obsessive-compulsive disorder
Noh, H. J., Tang, R., Flannick, J. A., O'Dushlaine, C. T., Swofford, R., Howrigan, D. P., Genereux, D. P., Johnson, J., van Grootheest, G., Grünblatt, E., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00831-x · Cited by 69
Cholesterol: The Good, the Bad, and the Ugly - Therapeutic Targets for the Treatment of Dyslipidemia
Elshourbagy, N. A., Meyers, H. V., & Abdel‐Meguid, S. S. (2013) · Medical Principles and Practice · doi:10.1159/000356856 · Cited by 70
Emerging therapeutic agents to lower lipoprotein (a) levels
Kolski, B. C., & Tsimikas, S. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283598d81 · Cited by 64
Proprotein convertase subtilisin–kexin type 9 is elevated in proteinuric subjects: Relationship with lipoprotein response to antiproteinuric treatment
Kwakernaak, A. J., Lambert, G. C., Slagman, M. C. J., Waanders, F., Laverman, G. D., Petrides, F., Dikkeschei, B. D., Navis, G. J., & Dullaart, R. P. F. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.11.009 · Cited by 65
Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials
Ridker, P. M., Amarenco, P., Brunell, R., Glynn, R. J., Jukema, J. W., Kastelein, J. J. P., Köenig, W., Nissen, S. E., Revkin, J. H., Santos, R. D., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.05.010 · Cited by 62
A Randomized Study of the Relative Pharmacokinetics, Pharmacodynamics, and Safety of Alirocumab, a Fully Human Monoclonal Antibody to PCSK 9, After Single Subcutaneous Administration at Three Different Injection Sites in Healthy Subjects
Lunven, C., Paehler, T., Poitiers, F., Brunet, A., Rey, J., Hanotin, C., & Sasiela, W. J. (2014) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12093 · Cited by 61
Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence
Ferri, N., Corsini, A., Macchi, C., Magni, P., & Ruscica, M. (2015) · Translational research · doi:10.1016/j.trsl.2015.10.004 · Cited by 63
Using ALoFT to determine the impact of putative loss-of-function variants in protein-coding genes
Balasubramanian, S., Fu, Y., Pawashe, M., McGillivray, P. D., Jin, M., Liu, J., Karczewski, K. J., MacArthur, D. G., & Gerstein, M. (2017) · Nature Communications · doi:10.1038/s41467-017-00443-5 · Cited by 62
Elevated Plasma PCSK9 Level Is Equally Detrimental for Patients With Nonfamilial Hypercholesterolemia and Heterozygous Familial Hypercholesterolemia, Irrespective of Low-Density Lipoprotein Receptor Defects
Lambert, G. C., Petrides, F., Chatelais, M., Blom, D. J., Choque, B., Tabet, F., Wong, G., Rye, K., Hooper, A. J., Burnett, J. R., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.02.538 · Cited by 60
Understanding PCSK9 and anti-PCSK9 therapies
McKenney, J. M. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.01.001 · Cited by 62
PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia
Ito, M. K., & Santos, R. D. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.766 · Cited by 59
Recent Advances in Defining the Genetic Basis of Rheumatoid Arthritis
Terao, C., Raychaudhuri, S., & Gregersen, P. K. (2016) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-090314-045919 · Cited by 60
ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases
Luo, F., Das, A., Khetarpal, S. A., Fang, Z., Zelniker, T. A., Rosenson, R. S., & Qamar, A. (2023) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2023.01.008 · Cited by 58
The Central Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Septic Pathogen Lipid Transport and Clearance
Walley, K. R., Francis, G. A., Opal, S. M., Stein, E. A., Russell, J. A., & Boyd, J. H. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201505-0876ci · Cited by 58
Self-citation
Identification of a loss-of-function inducible degrader of the low-density lipoprotein receptor variant in individuals with low circulating low-density lipoprotein
Sorrentino, V., Fouchier, S. W., Motazacker, M. M., Nelson, J. K., Defesche, J. C., Dallinga‐Thie, G. M., Kastelein, J. J. P., Hovingh, G. K., & Zelcer, N. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs472 · Cited by 59
Proprotein Convertase Subtilisin/Kexin 9 Inhibitors
Dragan, S. R., Șerban, M.-C., & Banach, M. (2014) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248414539562 · Cited by 58
PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?
Banach, M., Rizzo, M., Obradovic, M. M., Montalto, G., Rysz, J., Mikhailidis, D. P., & Isenović, E. R. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990303 · Cited by 57
Structural Modification of Natural Product Ganomycin I Leading to Discovery of a α-Glucosidase and HMG-CoA Reductase Dual Inhibitor Improving Obesity and Metabolic Dysfunction in Vivo
Wang, K., Li, B., Zhou, N., Zhang, J., Liao, M., Zheng, Z., Wang, Y., Liu, C., Wang, J., Wang, L., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00107 · Cited by 57
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy
Joseph, L., & Robinson, J. G. (2015) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2015.04.004 · Cited by 59
Human Genetics in Rheumatoid Arthritis Guides a High-Throughput Drug Screen of the CD40 Signaling Pathway
Li, G., Diogo, D., Wu, D., Spoonamore, J., Dančík, V., Franke, L., Kurreeman, F. A. S., Rossin, E. J., Duclos, G. E., Hartland, C. L., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003487 · Cited by 56
Overcoming Challenges With Statin Therapy
Spence, J. D., & Dresser, G. K. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002497 · Cited by 57
Effects of RG7652, a Monoclonal Antibody Against PCSK9, on LDL-C, LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or With Established Coronary Heart Disease (from the Phase 2 EQUATOR Study)
Baruch, A., Mosesova, S., Davis, J. D., Budha, N. R., Vilimovskij, A., Kahn, R., Peng, K., Cowan, K. J., Harris, L. P., Gelzleichter, T. R., et al. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.02.020 · Cited by 56
Inclisiran for the treatment of dyslipidemia
Nishikido, T., & Ray, K. K. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1442435 · Cited by 60
PCSK9 inhibitors and reduction in cardiovascular events: Current evidence and future perspectives
Nicholls, S. J. (2023) · Kardiologia Polska · doi:10.33963/kp.a2023.0030 · Cited by 58
PCSK9 rs11591147 R46L loss‐of‐function variant protects against liver damage in individuals with NAFLD
Grimaudo, S., Bartesaghi, S., Rametta, R., Marra, F., Mancina, R. M., Pihlajamäki, J., Kakol‐Palm, D., Andréasson, A., Dongiovanni, P., Fracanzani, A. L., et al. (2020) · Liver International · doi:10.1111/liv.14711 · Cited by 54
microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production
Dong, J., He, M., Li, J., Pessentheiner, A., Wang, C., Zhang, J., Sun, Y., Wang, W.-T., Zhang, Y., Liu, J., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.143812 · Cited by 53
An Overview of the New Frontiers in the Treatment of Atherogenic Dyslipidemias
Rached, F. H., Chapman, M. J., & Kontush, A. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.85 · Cited by 55
Genomics in Cardiovascular Disease
Roberts, R., Marian, A. J., Dandona, S., & Stewart, A. F. R. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.12.054 · Cited by 53
Hypercholesterolemia As a Risk Factor for Cardiovascular Disease: Current Controversial Therapeutic Management
Zárate, A., Apolinar, L. M., Saucedo, R., Hernández-Valencia, M., & Basurto, L. (2016) · Archives of Medical Research · doi:10.1016/j.arcmed.2016.11.009 · Cited by 53
Whole Genome Association Study of the Plasma Metabolome Identifies Metabolites Linked to Cardiometabolic Disease in Black Individuals
Tahir, U. A., Katz, D. H., Ávila-Pacheco, J., Bick, A. G., Pampana, A., Robbins, J., Yu, Z., Chen, Z., Benson, M. D., Cruz, D. E., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32275-3 · Cited by 52
Discovery of rare variants for complex phenotypes
Kosmicki, J. A., Churchhouse, C. L., Rivas, M. A., & Neale, B. M. (2016) · Human Genetics · doi:10.1007/s00439-016-1679-1 · Cited by 54
Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013
Suh, H. Y., Peck, C., Yu, K.-S., & Lee, H. (2016) · Drug Design, Development and Therapy · doi:10.2147/dddt.s121520 · Cited by 51
Genome-wide association studies to advance our understanding of critical cell types and pathways in rheumatoid arthritis
Diogo, D., Okada, Y., & Plenge, R. M. (2013) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000012 · Cited by 54
Genetic Risk Stratification
Roberts, R., Chang, C. C., & Hadley, T. D. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2020.09.004 · Cited by 54
Reviewing the role of healthy volunteer studies in drug development
Karakunnel, J. J., Bui, N. Q., Palaniappan, L. P., Schmidt, K. T., Mahaffey, K. W., Morrison, B. W., Figg, W. D., & Kummar, S. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1710-5 · Cited by 50
Precision annotation of digital samples in NCBI’s gene expression omnibus
Hadley, D., Pan, J., El-Sayed, O. M., Aljabban, J., Aljabban, I., Azad, T. D., Hadied, M. O., Raza, S., Rayikanti, B. A., Chen, B., et al. (2017) · Scientific Data · doi:10.1038/sdata.2017.125 · Cited by 50
Alirocumab for Hyperlipidemia: Physiology of PCSK9 inhibition, Pharmacodynamics and Phase I and Ii Clinical Trial Results of a PCSK9 Monoclonal Antibody
Roth, E. M., & Diller, P. M. (2014) · Future Cardiology · doi:10.2217/fca.13.107 · Cited by 49
Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice
Berger, J., Loza‐Valdes, A., Gromada, J., Anderson, N. N., & Horton, J. D. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m076844 · Cited by 51
A Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic Populations
Gadkar, K., Budha, N., Baruch, A., Davis, J. D., Fielder, P., & Ramanujan, S. (2014) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2014.47 · Cited by 48
Current perspectives in genetic cardiovascular disorders: from basic to clinical aspects
Kawashiri, M., Hayashi, K., Konno, T., Fujino, N., Ino, H., & Yamagishi, M. (2013) · Heart and Vessels · doi:10.1007/s00380-013-0391-5 · Cited by 48
Proprotein convertase subtilisin/kexin type 9 inhibition
Marais, D. A., Blom, D. J., Petrides, F., Gouëffic, Y., & Lambert, G. C. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283587563 · Cited by 49
A genetic basis for coronary artery disease
Roberts, R. (2014) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2014.10.008 · Cited by 48
Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?
Banerjee, Y., Santos, R. D., Al‐Rasadi, K., & Rizzo, M. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.02.018 · Cited by 49
Genome‐wide and Phenome‐wide Approaches to Understand Variable Drug Actions in Electronic Health Records
Robinson, J. R., Denny, J. C., Roden, D. M., & Driest, S. L. V. (2017) · Clinical and Translational Science · doi:10.1111/cts.12522 · Cited by 51
Reduced plasma PCSK 9 response in patients with bacteraemia is associated with mortality
Rannikko, J., Sanz, D. J., Ortutay, Z., Seiskari, T., Aittoniemi, J., Huttunen, R., Syrjänen, J., & Pesu, M. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12946 · Cited by 50
Inclisiran in lipid management: A Literature overview and future perspectives
Scicchitano, P., Milo, M., Mallamaci, R., Palo, M. D., Caldarola, P., Massari, F., Gabrielli, D., Colivicchi, F., & Ciccone, M. M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112227 · Cited by 47
Anti-PCSK9 therapies for the treatment of hypercholesterolemia
Hooper, A. J., & Burnett, J. R. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.748743 · Cited by 46
Lupin protein exerts cholesterol-lowering effects targeting PCSK9: From clinical evidences to elucidation of the in vitro molecular mechanism using HepG2 cells
Lammi, C., Zanoni, C., Calabresi, L., & Arnoldi, A. (2016) · Journal of Functional Foods · doi:10.1016/j.jff.2016.02.042 · Cited by 46
Keep recycling going: new approaches to reduce LDL-C
Klein-Szanto, A. J. P., & Bassi, D. E. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.04.003 · Cited by 46
Antihyperlipidemic Therapies Targeting PCSK9
Weinreich, M. A., & Frishman, W. H. (2014) · Cardiology in Review · doi:10.1097/crd.0000000000000014 · Cited by 46
Design and Rationale of the LAPLACE‐TIMI 57 Trial: A Phase II, Double‐Blind, Placebo‐Controlled Study of the Efficacy and Tolerability of a Monoclonal Antibody Inhibitor of PCSK9 in Subjects With Hypercholesterolemia on Background Statin Therapy
Kohli, P., Desai, N. R., Giugliano, R. P., Kim, J. B., Somaratne, R. M., Huang, F., Knüsel, B., McDonald, S. T., Abrahamsen, T. E., Wasserman, S. M., et al. (2012) · Clinical Cardiology · doi:10.1002/clc.22014 · Cited by 45
Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk
Rosei, E. A., & Salvetti, M. (2016) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-016-0155-2 · Cited by 47
PCSK9: from biology to clinical applications
Blanchard, V., Khantalin, I., Ramin‐Mangata, S., Chemello, K., Nativel, B., & Lambert, G. C. (2018) · Pathology · doi:10.1016/j.pathol.2018.10.012 · Cited by 47
Development of the novel ACLY inhibitor 326E as a promising treatment for hypercholesterolemia
Xie, Z., Zhang, M., Song, Q., Cheng, L., Zhang, X., Song, G., Sun, X., Gu, M., Zhou, C., Zhang, Y., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.06.011 · Cited by 45
Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran)
Sinning, D., & Landmesser, U. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01427-6 · Cited by 44
Relationship Between Low‐Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid‐Lowering Strategies
Rey, J., Poitiers, F., Paehler, T., Brunet, A., DiCioccio, A. T., Cannon, C. P., Surks, H. K., Pinquier, J., Hanotin, C., & Sasiela, W. J. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.003323 · Cited by 44
Fibrin Clot Properties in Atherosclerotic Vascular Disease: From Pathophysiology to Clinical Outcomes
Ząbczyk, M., Natorska, J., & Undas, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132999 · Cited by 44

Authors: Stein, E. A., Mellis, S., Yancopoulos, G. D., Stahl, N., Logan, D., Smith, W. B., Lisbon, E., Gutierrez, M., Webb, C., Wu, R., Du, Y., Kranz, T., Gasparino, E., & Swergold, G. D.
Affiliations: Regeneron (United States) (US)
Medpace (United States) (US)
University of Tennessee Medical Center (US)
IQVIA (United States) (US)
ORCID: Stein, Evan A.
Mellis, Scott
Stahl, Neil
Lisbon, Eleanor
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2012-03-22
Volume: 366
Issue: 12
Pages: 1108-1118
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1105803
OpenAlex: W1989730880
Semantic Scholar: 04c1ea8c55c4bae0da3106e47141bac81e1bb585
Cited by: 664
References: 15
Citations by year: 2026: 12 · 2025: 11 · 2024: 29 · 2023: 22 · 2022: 19 · 2021: 20 · 2020: 38 · 2019: 29 · 2018: 46 · 2017: 58 · 2016: 62 · 2015: 86 · 2014: 83 · 2013: 92 · 2012: 57
FWCI: 103.85
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: Sanofi
Regeneron Pharmaceuticals
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords: PCSK9, monoclonal antibodies, LDL cholesterol, LDL receptor degradation, hypercholesterolemia, familial hypercholesterolemia, atorvastatin, lipid profile, adverse events, dose escalation, cholesterol absorption inhibition
MeSH terms: Atorvastatin, Proprotein Convertase 9, Adult, Antibodies, Monoclonal, Anticholesteremic Agents, Dose-Response Relationship, Drug, Drug Therapy, Combination, Female, Heptanoic Acids, Humans, Hypercholesterolemia, Hyperlipoproteinemia Type II, Injections, Intravenous, Injections, Subcutaneous, Lipoproteins, Cholesterol, LDL, Male, Middle Aged, Pyrroles, Receptors, LDL, Serine Endopeptidases, Least-Squares Analysis, Proprotein Convertases, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks